Starton Therapeutics Terminates Healthwell Acquisition Corp. I (HWEL) Deal
by Marlena Haddad on 2023-11-06 at 8:51am

Healthwell Acquisition Corp. I (Nasdaq: HWEL) announced on Friday evening that its former target Starton has terminated its business combination.

Although the parties did not provide extensive detail regarding the termination, they clarified that the deal fell through due to certain closing conditions not being satisfied by the outside date of November 3.

Healthwell I unveiled its $339 million combination with Starton earlier this year in April. While the two sides initially agreed on a $15 million closing condition, they later reduced this to $10 million in September.

The SPAC brought about $253.7 million into the deal through its trust, but following redemptions from previous votes, it was left with around $41.8 million. Despite the expectation of supplementing this with $15 million from a PIPE or a debt facility, there has been no confirmation of securing this funding.

Paramus, New Jersey-based Starton is developing a line of treatments to improve efficacies in delivering drugs for certain types of cancer and mitigating the side effects of chemotherapy. Going forward, Starton will continue its clinical efforts to meet the completion of its study for the advancement of its patients.

As a result of this termination, Healthwell I will seek an alternative business combination. With a completion deadline of December 5, it currently has just a month to find a suitable target to combine with. However, it recently filed a proxy to hold a shareholder meeting aimed at extending this deadline until August 2024, granting them a nine-month window to finalize a deal.

 

Recent Posts
by Kristi Marvin on 2024-04-20 at 11:45am

Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...

by Nicholas Alan Clayton on 2024-04-19 at 3:00pm

Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...

by Nicholas Alan Clayton on 2024-04-19 at 7:53am

At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...

by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved